ArticleCancer cell international2026
Comprehensive analysis of key palmitoylation-modifying enzymes in clear cell renal cell carcinoma: implications for prognosis and therapy.
Article in Cancer cell international, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Emerging roles of α/β hydrolase domain (ABHD) proteins in S-palmitoylation modification: molecular mechanisms, structural features, and pathological implications.Cellular & molecular biology letters · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
backgroundPalmitoylation, a key post-translational modification, plays a crucial role in tumor progression, yet its landscape in clear cell renal cell carcinoma (ccRCC) remains poorly characterized. This study aims to systematically identify and validate key palmitoylation-modifying enzymes in ccRCC and explore their clinical significance.
methodsWe integrated multi-omics data from TCGA-KIRC and GEO datasets to evaluate palmitoylation levels using the PalmScore system. Machine learning algorithms were applied to identify diagnostic and prognostic key genes. Functional roles of ZDHHC11 were validated in vitro using siRNA-mediated knockdown in ccRCC cell lines. Single-cell RNA sequencing data further confirmed expression patterns.
resultsPalmScore effectively stratified ccRCC patients into high- and low-risk groups, with the high PalmScore group showing enriched immune infiltration and poorer survival outcomes. Machine learning identified ZDHHC2 and ABHD17C as diagnostic markers, while ZDHHC11 emerged as a prognostic key gene. In vitro experiments demonstrated that ZDHHC11 knockdown significantly suppressed proliferation, migration, and invasion in ccRCC cells. Single-cell analysis validated the expression patterns of these key genes across different cell types. DISCUSSION: Our study unveils the critical roles of palmitoylation-modifying enzymes in ccRCC progression and immune regulation. The identified key genes hold promise as biomarkers for diagnosis and prognosis, offering potential targets for future therapeutic strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.